Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient’s lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower sensitivity to daratumumab. ISB 1342 is a bispe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouleau, Blandine, Estoppey, Carole, Suere, Perrine, Nallet, Emilie, Laurendon, Amélie, Monney, Thierry, Pais Ferreira, Daniela, Drake, Adam, Carretero-Iglesia, Laura, Macoin, Julie, Berret, Jérémy, Pihlgren, Maria, Doucey, Marie-Agnès, Gudi, Girish S., Menon, Vinu, Udupa, Venkatesha, Maiti, Abhishek, Borthakur, Gautam, Srivastava, Ankita, Blein, Stanislas, Mbow, M. Lamine, Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M., Edwards, James R., Menoret, Emmanuelle, Kervoëlen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Zhukovsky, Eugene, Perro, Mario, Chimen, Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644056/
https://www.ncbi.nlm.nih.gov/pubmed/37192303
http://dx.doi.org/10.1182/blood.2022019451

Ejemplares similares

Ejemplares similares